Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery

Azevedo, Cláudia; Pinto, Soraia; Benjakul, Sopisa; Nilsen, Jeannette; Santos, Hélder A.; Traverso, Giovanni; Andersen, Jan Terje; Sarmento, Bruno

doi:10.1016/j.addr.2021.04.016

Cited by 14 publications

(6 citation statements)

References 239 publications

(485 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Such a need is not limited to refractory patients but should concern all patients. Most recently, biologics targeting compounds of the immunological system, such as B cells (46-49), pro-inflammatory cytokines (50, 51), and their receptors (52, 53), complement system (54), and Fc neonatal receptor (55)(56)(57), are emerging as promising critical therapeutic tools to provide faster symptoms remission and better corticosteroid-sparing effects than conventional treatments. It is noteworthy that RTX can be tried in patients with MG who have failed to respond to glucocorticoid and conventional immunosuppressive drug therapy (Class IV evidence), especially in patients with MusK-MG (58).…”

Section: Discussionmentioning

confidence: 99%

Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis

Jiang

Su²,

Chang³

2023

Front. Immunol.

View full text Add to dashboard Cite

BackgroundMyasthenia gravis (MG) is an autoimmune disease with acquired neuromuscular junction transmission disorders. In the last two decades, various pathogenesis, application of immunosuppressive agents, and targeted immunotherapy have been significant events. However, extracting the most critical information from complex events is very difficult to guide clinical work. Therefore, we used bibliometrics to summarize and look forward.MethodsScience Citation Index Expanded (SCI-E) from the Web of Science Core Collection (WoSCC) database was identified as a source of material for obtaining MG-related articles. Scimago Graphica, CiteSpace, VOSviewer, and bibliometrix were utilized for bibliometric analysis. Knowledge network graphs were constructed and visualized; countries, institutions, authors, journals, references, and keywords were evaluated. In addition, GraphPad Prism and Microsoft Excel 365 were applied for statistical analysis.ResultsAs of October 25, 2022, 9,970 original MG-related articles were used for the bibliometric analysis; the cumulative number of citations to these articles was 236,987, with an H-index of 201. The United States ranked first in terms of the number of publications (2,877) and H-index (134). Oxford has the highest H-index (67), and Udice French Research University has the highest number of publications (319). The author with the highest average number of citations (66.19), publications (151), and H-index (53) was Vincent A. 28 articles have remained in an explosive period of citations. The final screening yielded predictive keywords related to clinical trials and COVID-19.ConclusionWe conducted a bibliometric analysis of 9,970 original MG-related articles published between 1966 and 2022. Ultimately, we found that future MG research hotspots include two major parts: (1) studies directly related to MG disease itself: clinical trials of various targeted biological agents; the relationship between biomarkers and therapeutic decisions, pathogenesis and outcome events, ultimately serving individualized management or precision therapy; (2) studies related to MG and COVID-19: different variants of COVID-19 (e.g., Omicron) on MG adverse outcome events; assessment of the safety of different COVID-19 vaccines for different subtypes of MG.

show abstract

Section: Discussionmentioning

confidence: 99%

Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis

Jiang

Su²,

Chang³

2023

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…In contrast, a reasonably evident transcytosis mediated by the neonatal Fc receptor (FcRn, which can bind to the Fc domain of immunoglobulin G (IgG) or albumin) has the potential to enhance the bioavailability of orally delivered drugs. [ 144 , 145 ] FcRn is expressed on the epithelium. As a result, nanomaterials containing the Fc component of IgG or albumin bind FcRn at the apical surface of epithelial cells.…”

Section: Nanomaterials For Diabetes Prevention and Therapymentioning

confidence: 99%

Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Liu

Zeng

et al. 2021

Advanced Science

Self Cite

View full text Add to dashboard Cite

Diabetes mellitus (DM) refers to a group of metabolic disorders that are characterized by hyperglycemia. Oral subcutaneously administered antidiabetic drugs such as insulin, glipalamide, and metformin can temporarily balance blood sugar levels, however, long‐term administration of these therapies is associated with undesirable side effects on the kidney and liver. In addition, due to overproduction of reactive oxygen species and hyperglycemia‐induced macrovascular system damage, diabetics have an increased risk of complications. Fortunately, recent advances in nanomaterials have provided new opportunities for diabetes therapy and diagnosis. This review provides a panoramic overview of the current nanomaterials for the detection of diabetic biomarkers and diabetes treatment. Apart from diabetic sensing mechanisms and antidiabetic activities, the applications of these bioengineered nanoparticles for preventing several diabetic complications are elucidated. This review provides an overall perspective in this field, including current challenges and future trends, which may be helpful in informing the development of novel nanomaterials with new functions and properties for diabetes diagnosis and therapy.

show abstract

“…These bound ligands are subsequently transcytosed via endosomes and released outside cells at physiological pH. 18 Therefore, FcRn can form strong bonds in the acidic small intestine, where most drugs are absorbed. 19 Also, in mice with hFcRn transgenes, human serum albumin (HSA) migrates more efficiently than human immunoglobulin G (hIgG) through mucosal lung barriers in vivo.…”

Section: Introductionmentioning

confidence: 99%

“…Substances with Fc portions of IgG or albumin can beneficially engage FcRn at the apical surface of epithelial cells, preventing lysosomal degradation. These bound ligands are subsequently transcytosed via endosomes and released outside cells at physiological pH . Therefore, FcRn can form strong bonds in the acidic small intestine, where most drugs are absorbed .…”

Section: Introductionmentioning

confidence: 99%

Prevention of Hypercholesterolemia with “Liposomes in Microspheres” Composite Carriers: A Promising Approach for Intestinal-Targeted Oral Delivery of Astaxanthin

Liu,

He,

Liu

et al. 2024

J. Agric. Food Chem.

View full text Add to dashboard Cite

Cardiovascular diseases are caused by hypercholesterolemia. Astaxanthin (AST) has been reported to exhibit antioxidant and anti-inflammatory properties. However, its bioavailability is poor because of low solubility and instability. In order to improve the bioavailability of AST, we developed an intestinal-responsive composite carrier termed as "liposomes in micropheres" incorporating N-succinyl-chitosan (NSC)-poly(ethylene glycol) (PEG) liposomes that functionalized by neonatal Fc receptors (FcRn) into hydrogels of sodium alginate (SA) and carboxymethyl chitosan (CMCS). In the AST NSC/HSA-PEG liposomes@SA/ CMCS microspheres, the AST's encapsulation efficiency (EE) was 96.26% (w/w) and its loading capacity (LC) was 6.47% (w/w). AST NSC/HSA-PEG liposomes had stability in the gastric conditions and achieved long-term release of AST in intestinal conditions. Then, AST NSC/HSA-PEG liposomes@SA/CMCS bind to intestinal epithelial cell targets by the neonatal Fc receptor.In vitro permeation studies show that there was a 4-fold increase of AST NSC/HSA-PEG liposomes@SA/CMCS in AST permeation across the intestinal epithelium. Subsequent in vivo experiments demonstrated that the composite carrier exhibited a remarkable mucoadhesive capacity, allowing for extended intestinal retention of up to 12 h, and it displayed deep penetration through the mucus layer, efficiently entering the intestinal villi epithelial cells, and enhancing the absorption of AST and its bioavailability in vivo. And oral administration of AST NSC/HSA-PEG liposomes@SA/CMCS could effectively prevent hypercholesterolemia caused by a highfat, high-cholesterol diet (HFHCD). These advancements highlight the potential of NSC/HSA-PEG liposomes@SA/CMCS composite carriers for targeted and oral uptake of hydrophobic bioactives.

show abstract

Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery

Abstract: Prevention of diabetes-associated fibrosis: Strategies in FcRn-targeted nanosystems for oral drug delivery, Advanced Drug Delivery Reviews (2021), doi:

Cited by 14 publications

References 239 publications

Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis

Knowledge mapping of global trends for myasthenia gravis development: A bibliometrics analysis

Emerging Theranostic Nanomaterials in Diabetes and Its Complications

Prevention of Hypercholesterolemia with “Liposomes in Microspheres” Composite Carriers: A Promising Approach for Intestinal-Targeted Oral Delivery of Astaxanthin

Contact Info

Product

Resources

About